Bharat Biotech announced on Monday that it has successfully made the Corona virus vaccine COVAXIN. The company said that it has successfully developed India's first vaccine for Kovid-19 in association with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
The company said that from next month the trial of this vaccine on humans will start. A statement issued by the company said that the SARS-COV-2 strain was isolated at the NIV based in Pune and transferred to Bharat Biotech. The domestic, inactivated vaccine has also been developed and developed at Bharat Biotech's BSL-3 (Bio-Safety Level 3) High Containment Facility located in Gnome Valley, Hyderabad.
At the same time, the Drug Controller General of India (DCGI), Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare have given permission to start Phase 1 and Phase 2 human clinical trials. Previously, the company had submitted results from preclinical studies. Human clinical trials are scheduled to begin across India next month.